|
US2020129549A1
|
|
Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative Recovery
|
|
US2020054622A1
|
|
Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
|
|
WO2020069008A1
|
|
Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
|
|
WO2020018343A1
|
|
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
|
|
US2019328782A1
|
|
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products
|
|
US2019350917A1
|
|
Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase
|
|
CA3076017A1
|
|
Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
|
|
AU2018257921A1
|
|
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
|
|
CA3058654A1
|
|
Methods and compositions for treating retina-associated disease using ccr3-inhibitors
|
|
CN110636844A
|
|
Methods and compositions for treating aging-related injuries using CCR 3-inhibitors
|
|
US2018110839A1
|
|
Blood plasma fractions as a treatment for aging-associated cognitive disorders
|
|
CA3033051A1
|
|
Blood plasma fractions as a treatment for aging-associated cognitive disorders
|
|
US2017340671A1
|
|
Blood plasma and plasma fractions as therapy for tumor growth and progression
|
|
US2013266646A1
|
|
Pharmaceutical formulations comprising CCR3 antagonists
|
|
KR20180005717A
|
|
Co-crystals and salts of ccr3-inhibitors
|
